Xeris Biopharma Holdings Watchlist

tz-plus logo Xeris Biopharma – 93% Recorlev Growth and New Billion-Dollar Revenue Target by 2030!

A. Zehetner
Reading Time: 3 minutes

Recorlev grows by 93%. More diagnoses and a doubled sales force drive demand. Xeris raises its forecast and aims to achieve annual revenues of over 1 billion USD by 2030. XP-8121 is expected to enable peak sales of 1 to 3 billion USD in thyroid therapies in the long term. Xeris Biopharma Holdings (XERS) markets three medications for hormonal and rare diseases. Since November 4, the stock has risen by 59%. After the massive breakout, it could advance to the highest price levels since 2019. Recorlev – New diagnoses and more doctors drive...

Read this article now with a free account.

Your benefits:

  • Every month, you can read 5 articles from the premium section for free.
  • Monthly 2 trial issues of the Trader newspaper for free.
  • Create a personal watchlist with an overview of news about your stock.
Trader Times
Free account
Here we go!
Image 1Image 2Image 3

Already registered? Log In